- $1 billion will expand Limerick's biologic active ingredient production.
- $800 million will expand Kinsale's diabetes and obesity treatment production.
- Limerick site to start production in 2026, creating 150 jobs.
- Limerick site to use 35% less energy, 40% less water, and generate 15% less waste.
Investment Overview
Eli Lilly and Company announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its Alzheimer's disease treatment. Additionally, the company unveiled an $800 million expansion of its Kinsale, Ireland, facility, which began producing diabetes and obesity treatments last year.
Expansion Details
The Limerick site will join Lilly's global manufacturing network, focusing on biologic active ingredients for Alzheimer's and other biologic medicines. The investment will create 150 jobs, bringing the total to 450 employees. Production is set to start in 2026, pending planning approval. The Kinsale facility employs continuous manufacturing technology for complex peptides and has been recognized for innovation by the International Society of Pharmaceutical Engineers.
Sustainability Initiatives
Lilly is committed to sustainability, with the Limerick site designed to operate with 35% lower energy intensity, use 40% less water, and generate 15% less waste than traditional processes. The Kinsale facility features the largest privately owned solar farm in Ireland, powering a significant portion of the site.
Workforce and Growth
Ireland's skilled workforce, regulatory environment, and pro-innovation policies have supported Lilly's nearly fifty-year presence in the country. The company's Global Business Solutions center in Cork has quadrupled employment since 2019, with over 2,000 employees expected by the end of 2024, more than half in clinical research and development.
